AzurRx BioPharma (NASDAQ:AZRX) received a $8.00 price target from equities researchers at HC Wainwright in a report released on Friday, November 17th. The brokerage presently has a “buy” rating on the stock. HC Wainwright’s price objective points to a potential upside of 160.59% from the company’s current price.
AzurRx BioPharma (AZRX) traded down $0.27 during mid-day trading on Friday, reaching $3.07. 38,283 shares of the company traded hands, compared to its average volume of 32,886. AzurRx BioPharma has a 52 week low of $2.40 and a 52 week high of $5.25.
A number of hedge funds have recently added to or reduced their stakes in AZRX. Susquehanna International Group LLP acquired a new stake in shares of AzurRx BioPharma during the 3rd quarter worth about $131,000. Parsons Capital Management Inc. RI lifted its stake in AzurRx BioPharma by 37.2% in the third quarter. Parsons Capital Management Inc. RI now owns 254,263 shares of the company’s stock valued at $1,015,000 after buying an additional 68,920 shares during the period. Ardsley Advisory Partners bought a new position in AzurRx BioPharma in the second quarter valued at approximately $141,000. Finally, IHT Wealth Management LLC boosted its stake in shares of AzurRx BioPharma by 15.3% during the 2nd quarter. IHT Wealth Management LLC now owns 3,498 shares of the company’s stock worth $486,000 after acquiring an additional 464 shares during the period. Hedge funds and other institutional investors own 8.18% of the company’s stock.
WARNING: “HC Wainwright Analysts Give AzurRx BioPharma (AZRX) a $8.00 Price Target” was originally reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this article on another website, it was illegally stolen and reposted in violation of United States & international copyright & trademark law. The correct version of this article can be read at https://ledgergazette.com/2017/12/07/azurrx-biopharm-azrx-given-a-8-00-price-target-by-hc-wainwright-analysts.html.
About AzurRx BioPharma
AzurRx BioPharma, Inc is a clinical development-stage biopharmaceutical company. The Company is engaged in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal (GI) disorders. The Company’s product pipeline consists of two therapeutic proteins, such as MS1819 and AZX1101.
Receive News & Ratings for AzurRx BioPharma Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AzurRx BioPharma Inc and related companies with MarketBeat.com's FREE daily email newsletter.